Deborah Mulford, M.D.

Biography

Awards

2004 - 2006
NIH Clinical Loan Repayment Program
Sponsor: NIH

2003 - 2005
Lauri Strauss Leukemia Foundation Endowed Fellowship
Sponsor: Lauri Strauss Leukemia Foundation
Location: Memorial Sloan-Kettering Cancer Center, New York City, NY

VIEW ALL expand_more

Clinical Trials

Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

Lead Researcher: Deborah Mulford MD

This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.

View Study Details

Publications

Journal Articles

10/23/2023
Hill BT, Ma S, Zent CS, Baran AM, Wallace DS, Advani AS, Winter AM, Winter JN, Gordon LI, Karmali R, Liesveld JL, Mulford DA, Rowland C, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Barr PM. "Response-Adapted, Time-Limited Venetoclax, Umbralisib and Ublituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia." Blood advances.. 2023 Oct 23; Epub 2023 Oct 23.

4/19/2022
Lissa D, Takahashi N, Desai P, Manukyan I, Schultz CW, Rajapakse V, Velez MJ, Mulford D, Roper N, Nichols S, Vilimas R, Sciuto L, Chen Y, Guha U, Rajan A, Atkinson D, El Meskini R, Weaver Ohler Z, Thomas A. "Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models." Nature communications.. 2022 Apr 19; 13(1):2023. Epub 2022 Apr 19.

6/23/2021
Roper N, Velez MJ, Chiappori A, Kim YS, Wei JS, Sindiri S, Takahashi N, Mulford D, Kumar S, Ylaya K, Trindade C, Manukyan I, Brown AL, Trepel JB, Lee JM, Hewitt S, Khan J, Thomas A. "Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer." Nature communications.. 2021 Jun 23; 12(1):3880. Epub 2021 Jun 23.

Books & Chapters

2006
Chapter Title: Monoclonal Antibody Therapies of Cancer
Book Title: Cancer Chemotherapy and Biotherapy
Author List: Scheinberg DA, Mulford DA, Jurcic JG, Junghans RP, Sgouros G.
Published By: Baltimore: Lippincott, Williams, And Wilkins 2006

VIEW ALL PUBLICATIONS

Reviews

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.